Core Laboratories (NYSE: CLB) director gets 7,895-share stock grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Core Laboratories Inc. director Harvey Robert Klingensmith reported equity compensation activity in company stock. He received a grant of 7,895 Restricted Shares on April 1, 2026 at a price of $0.00 per share. According to the terms, these Restricted Shares will vest at the end of a one-year vesting period on April 1, 2027, and are subject to a deferral election, with vested shares distributed as common stock after his separation of service from the Board. On the same date, 8,069 previously granted Restricted Shares vested at the end of their one-year vesting period and were converted into 8,069 shares of Common Stock at $0.00 per share. Following these transactions, Klingensmith directly holds 50,031 shares of Core Laboratories common stock.

Insider Trade Summary

8,069 shares exercised/converted

Mixed 3 txns

Insider Klingensmith Harvey Robert

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Shares	7,895	$0.00	--
Exercise	Restricted Shares	8,069	$0.00	--
Exercise	Common Stock	8,069	$0.00	--

Holdings After Transaction: Restricted Shares — 7,895 shares (Direct); Common Stock — 50,031 shares (Direct)

Footnotes (1)

The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2027, subject to the terms of issuance. Such shares remain subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2, and the vested portion thereof will be distributed as shares of common stock following the Reporting Person's separation of service from the Board. The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2026.

Key Figures

Restricted Shares Granted: 7,895 shares Restricted Shares Vested and Converted: 8,069 shares Common Shares Held After Transactions: 50,031 shares +1 more

4 metrics

Restricted Shares Granted 7,895 shares Grant on April 1, 2026 at $0.00 per share

Restricted Shares Vested and Converted 8,069 shares Vested and converted to Common Stock on April 1, 2026

Common Shares Held After Transactions 50,031 shares Direct holdings after April 1, 2026 transactions

Vesting Date for New Grant April 1, 2027 End of one-year vesting period for 7,895 Restricted Shares

Key Terms

Restricted Shares, vesting period, deferral election, Treasury Regulation 1.409A-2, +1 more

5 terms

Restricted Shares financial

"The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period"

Restricted shares are company stock that cannot be sold or transferred immediately because they are subject to legal or contractual limits, such as a required holding period or performance conditions. They matter to investors because these locked-up shares can affect a company’s available stock for trading, future dilution, and insider incentives—imagine a gift that can’t be cashed until certain conditions are met, which changes when and how much supply can suddenly enter the market.

vesting period financial

"The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2026."

A vesting period is the set amount of time someone must wait before they fully own granted shares, stock options, or other equity tied to their work or an agreement; ownership increases gradually or in steps during that time. Investors care because vesting determines when insiders or employees can sell shares, which affects future supply of stock, company incentives and executive retention—think of it like unlocking ownership over installments rather than receiving it all at once.

deferral election financial

"Such shares remain subject to a deferral election by the Reporting Person"

Treasury Regulation 1.409A-2 financial

"in accordance with Treasury Regulation 1.409A-2, and the vested portion thereof will be distributed"

separation of service financial

"distributed as shares of common stock following the Reporting Person's separation of service from the Board."

Form 4 Insider Transactions: What Each Field Means →

04/07/2026 - 07:46 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Klingensmith Harvey Robert

(Last)

(First)

(Middle)

6316 WINDFERN ROAD

(Street)

HOUSTON

TEXAS

77040

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Core Laboratories Inc. /DE/ [ CLB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/01/2026		M		8,069	A	$0	50,031	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Shares	$0	04/01/2026		A		7,895		⁽¹⁾	⁽¹⁾	Common Stock	7,895	$0	7,895	D
Restricted Shares	$0	04/01/2026		M			8,069	⁽²⁾	⁽²⁾	Common Stock	8,069	$0	0	D

Explanation of Responses:

1. The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2027, subject to the terms of issuance. Such shares remain subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2, and the vested portion thereof will be distributed as shares of common stock following the Reporting Person's separation of service from the Board.

2. The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2026.

	/s/ Mark Tattoli, Attorney-in-Fact	04/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did CLB director Harvey Robert Klingensmith report?

Harvey Robert Klingensmith reported a grant of 7,895 Restricted Shares and the vesting and conversion of 8,069 Restricted Shares into Common Stock. All transactions occurred on April 1, 2026 as part of his equity compensation, with no open-market purchases or sales disclosed.

How many Core Laboratories (CLB) Restricted Shares were granted to the director?

He was granted 7,895 Restricted Shares at a price of $0.00 per share. These shares are scheduled to vest after a one-year vesting period ending on April 1, 2027, subject to the terms of issuance and a potential deferral election by the director.

When do the newly granted CLB Restricted Shares to the director vest?

The 7,895 newly granted Restricted Shares will vest on April 1, 2027, following a one-year vesting period. After vesting, the shares may be deferred and will be distributed as common stock following the director’s separation of service from the Core Laboratories Board.

What happened to the previously issued Restricted Shares for CLB’s director?

A prior grant of 8,069 Restricted Shares completed its one-year vesting period on April 1, 2026. Those vested Restricted Shares were then converted into 8,069 shares of Core Laboratories Common Stock at $0.00 per share, increasing the director’s directly held common shares.

How many Core Laboratories (CLB) common shares does the director hold after these transactions?

After the vesting and conversion of 8,069 Restricted Shares, the director directly holds 50,031 shares of Core Laboratories Common Stock. This figure reflects his position following the April 1, 2026 transactions reported in the insider filing.

Were any Core Laboratories (CLB) shares sold or bought on the market by the director?

No open-market purchases or sales were reported. The filing shows equity compensation events only: a grant of 7,895 Restricted Shares and the vesting and conversion of 8,069 Restricted Shares into Common Stock at $0.00 per share, all directly held by the director.